The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment. / Kloppenborg, Julie T.; Gamborg, Michael; Fonvig, Cilius E.; Nielsen, Tenna R.H.; Pedersen, Oluf; Johannesen, Jesper; Hansen, Torben; Holm, Jens-Christian.
In: Pediatric Diabetes, Vol. 19, No. 3, 2018, p. 366-374.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment
AU - Kloppenborg, Julie T.
AU - Gamborg, Michael
AU - Fonvig, Cilius E.
AU - Nielsen, Tenna R.H.
AU - Pedersen, Oluf
AU - Johannesen, Jesper
AU - Hansen, Torben
AU - Holm, Jens-Christian
N1 - Funding information The Novo Nordisk Foundation, Grant/Award number: NNF15OC0016544; Novo Nordisk, Grant/Award number: unrestricted educational grant; The Danish Innovation Foundation, Grant/Award number: 0603‐00457B; The Region Zealand Health Scientifics Research Foundation
PY - 2018
Y1 - 2018
N2 - OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.
AB - OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.
KW - Journal Article
KW - Body Mass Index
KW - Glucose Intolerance/blood
KW - Humans
KW - Insulin/blood
KW - Blood Glucose
KW - Male
KW - Prediabetic State/blood
KW - Pediatric Obesity/blood
KW - Young Adult
KW - Weight Loss
KW - Adolescent
KW - Female
KW - Glycated Hemoglobin A/metabolism
KW - C-Peptide/blood
KW - Weight Reduction Programs/statistics & numerical data
KW - Child
KW - Longitudinal Studies
KW - prediabetes
KW - weight loss
KW - children
KW - impaired glucose metabolism
KW - obesity
U2 - 10.1111/pedi.12605
DO - 10.1111/pedi.12605
M3 - Journal article
C2 - 29159854
VL - 19
SP - 366
EP - 374
JO - Pediatric Diabetes
JF - Pediatric Diabetes
SN - 1399-543X
IS - 3
ER -
ID: 189863928